Small-Cell Lung Cancer | Current Treatment: Physician Insights | US | 2021
Treatment of small-cell lung cancer (SCLC) has long been dominated by chemo(radio)therapy, but the standard of care for first-line extensive-stage SCLC recently changed, following the FDA’s approval of Roche / Genentech’s Tecentriq (2019) and AstraZeneca’s Imfinzi (2020); both PD-L1 inhibitors are prescribed in combination with chemotherapy. The FDA approvals of PharmaMar / Jazz Pharmaceuticals’ Zepzelca and G1 Therapeutics’ Cosela have also expanded the treatment options for patients with extensive-stage SCLC. This content will explore U.S. physicians’ prescribing behavior when treating SCLC.
QUESTIONS ANSWERED
- What are physicians’ standard treatment practices for limited- and extensive-stage SCLC?
- What is the uptake of PharmaMar / Jazz Pharmaceuticals’ Zepzelca in patients with metastatic SCLC who have progressed on or after prior platinum-based therapy?
- How do drug-treatment rates vary across limited- and extensive-stage SCLC populations, according to the line of therapy?
- What are the key drivers and obstacles determining current prescribing of immune checkpoint inhibitors for extensive-stage SCLC? How do physicians differentiate between Tecentriq and Imfinzi in the first-line extensive-stage SCLC setting?
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 100 medical oncologists in the United States fielded in June 2021
Key drugs: Cosela, Imfinzi, Tecentriq, Zepzelca
